|本期目录/Table of Contents|

[1]王福川,董 漪,张 敏.直接抗病毒药物对儿童慢性丙型肝炎的治疗进展[J].传染病信息,2019,04:379-382.
 WANG Fu-chuan,DONG Yi,ZHANG Min*.Progress of direct-acting antiviral agents in the treatment of children with chronic hepatitis C[J].Infectious Disease Information,2019,04:379-382.
点击复制

直接抗病毒药物对儿童慢性丙型肝炎的治疗进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年04期
页码:
379-382
栏目:
综述
出版日期:
2019-09-12

文章信息/Info

Title:
Progress of direct-acting antiviral agents in the treatment of children with chronic hepatitis C
文章编号:
 1007-8134(2019)04-0379-04
作者:
王福川董 漪张 敏
100039 北京,中国人民解放军总医院第五医学中心青少年肝病诊疗与研究中心(王福川、董漪、张敏)
Author(s):
WANG Fu-chuan DONG Yi ZHANG Min*
Center for Diagnosis, Treatment and Research of Adolescent Liver Diseases, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
*Corresponding author, E-mail: gcmw2001@163.com
关键词:
慢性丙型肝炎儿童直接抗病毒药物
Keywords:
chronic hepatitis C children DAAs
分类号:
R512.63 
DOI:
10.3969/j.issn.1007-8134.2019.04.025
文献标识码:
A
摘要:
 聚乙二醇干扰素α-2a 或α-2b 联合利巴韦林是目前治疗儿童慢性丙型肝炎的标准方案。该方案最早应用于成人, 对HCV 的有效率仅约50%,并且对于儿童HCV 的治疗有效率最高也只达70%。近年来,直接作用于HCV 基因靶点的抗病 毒药物(direct-acting antiviral agents, DAAs)不断被研发出来,对HCV 的治疗起到质的飞跃,但该类药物在儿童HCV 治疗 中的应用大多处在临床试验阶段。本文通过对目前DAAs 在儿童慢性丙型肝炎中的研究进展作一综述,以期为HCV 患儿的 临床治疗提供参考依据。
Abstract:
Pegylated interferon alpha-2a or alpha-2b combined with ribavirin is the standard regimen for the treatment of children with chronic hepatitis C. This regimen is first applied to adults, and the effective rate to HCV is about 50%, the effective rate to HCV in children is only 70%. In recent years, many direct-acting antiviral agents (DAAs) directly targeting HCV genes have been developed and made great progress in treatment of HCV. The application of DAAs in the treatment of HCV among children is mostly at the stage of clinical trials. This article reviews the research progress of DAAs in children with chronic hepatitis C in order to provide reference for clinical treatment of children with HCV.

参考文献/References


[1] Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J]. J Hepatology, 2015, 61(1):77-87.
[2] Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(Suppl 1):S45-S57.
[3] Jhaveri R, Grant W, Kauf TL, et al. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period[J]. J Pediatr, 2006, 148(3):353-358.
[4] Negro F. Epidemiology of hepatitis C in Europe[J]. Dig Liver Dis, 2014, 46 (Suppl 5):S158-S164.
[5] Chen Y, Li L, Cui F, et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol, 2011, 32(9):888- 891.
[6] Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2):373- 395.
[7] Yang W, Jie Y, Center LD, et al. Introduction to hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus(2015)[J]. Chin J Gastroenterol Hepatol, 2016, 25(4):361-366.
[8] Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies[J]. Nat Med, 2013,19(7):837-849.
[9] Schmidt WN, Nelson DR, Pawlotsky JM, et al. Direct-acting antiviral agents and the path to interferon independence[J]. Clin Gastroenterol Hepatol 2014,12(5):728-737.
[10] Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral[J]. World J Gastroenterol, 2018, 24(24):2555-2566.
[11] Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection[J]. Hepatology, 2017, 66(2):371-378.
[12] Murray KF, Balistreri W, Bansal S, et al. Ledipasvir/ sofosbuvir±ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection[J]. J Hepatol, 2017, 66(Suppl 1):S57-S58.
[13] Leung DH, Wirth S, Yao BB. Ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4[J]. Hepatol Commun, 2018, 2(11):1311-1319.
[14] Yakoot M. Dual Sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection[J]. J Pediatr Gastroenterol Nutr, 2018, 67(1):1-19.
[15] El-Khayat HR, Kamal EM, El-Sayed MH, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience[J]. Aliment Pharmacol Ther, 2018, 47(6):1-7.
[16] El-Shabrawi MH, Kamal NM, El-Khayat HR, et al. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children[J]. Aliment Pharmacol Ther, 2018, 47(12):1699-1704.
[17] Li X, Chen H, Niu J, et al. Pharmacokinetics, safety, and tolerability of the direct-acting hepatitis C antiviral sofosbuvir in healthy chinese subjects[J]. 2018, 40(9):1556-1566.
[18] Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen[J]. 2017, 66(4):1083-1089.
[19] 纪冬,陈国凤. 慢性丙型肝炎的治愈之路[J]. 传染病信息, 2018,31(3):199-202.

备注/Memo

备注/Memo:

[ 通信作者] 张敏,E-mail: gcmw2001@163.com
更新日期/Last Update: 2019-09-15